RhumbLine Advisers: Acadia Pharmaceuticals ACAD Historial de posiciones en acciones
Comprado
Mantenidas
Vendido
| Trimestre | Valor de mercado | Estado | Acciones |
Cambio en la posición | Valor operado | Peso en el portafolio | Puesto en el portafolio | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | USD 6.66 M | Compra |
330,546
+27,644
| +9% | +USD 742 k | 0.01% | 1274 |
|
|
2026
Q2 | USD 7.66 M | Venta |
302,902
-52,559
| -15% | -USD 1.16 M | 0.01% | 1238 |
|
|
2026
Q1 | USD 7.91 M | Venta |
355,461
-5,625
| -2% | -USD 134 k | 0.01% | 1178 |
|
|
2025
Q4 | USD 9.6 M | Venta |
361,086
-30,463
| -8% | -USD 728 k | 0.01% | 1074 |
|
|
2025
Q3 | USD 8.36 M | Compra |
391,549
+24,463
| +7% | +USD 579 k | 0.01% | 1165 |
|
|
2025
Q2 | USD 7.92 M | Compra |
367,086
+14,370
| +4% | +USD 267 k | 0.01% | 1169 |
|
|
2025
Q1 | USD 5.86 M | Compra |
352,716
+177,188
| +101% | +USD 3.22 M | 0.01% | 1273 |
|
|
2024
Q4 | USD 3.22 M | Venta |
175,528
-2,613
| -1% | -USD 42.2 k | ﹤0.01% | 1637 |
|
|
2024
Q3 | USD 2.74 M | Venta |
178,141
-8,359
| -4% | -USD 139 k | ﹤0.01% | 1724 |
|
|
2024
Q2 | USD 3.03 M | Compra |
186,500
+2,121
| +1% | +USD 34.2 k | ﹤0.01% | 1668 |
|
|
2024
Q1 | USD 3.41 M | Compra |
184,379
+1,095
| +0.6% | +USD 27.1 k | ﹤0.01% | 1618 |
|
|
2023
Q4 | USD 5.74 M | Venta |
183,284
-1,116
| -0.6% | -USD 26.7 k | 0.01% | 1332 |
|
|
2023
Q3 | USD 3.84 M | Compra |
184,400
+3,624
| +2% | +USD 98.4 k | ﹤0.01% | 1499 |
|
|
2023
Q2 | USD 4.33 M | Compra |
180,776
+6,977
| +4% | +USD 155 k | ﹤0.01% | 1464 |
|
|
2023
Q1 | USD 3.27 M | Compra |
173,799
+917
| +0.5% | +USD 17.5 k | ﹤0.01% | 1561 |
|
|
2022
Q4 | USD 2.75 M | Compra |
172,882
+5,322
| +3% | +USD 83.2 k | ﹤0.01% | 1618 |
|
|
2022
Q3 | USD 2.74 M | Compra |
167,560
+16,545
| +11% | +USD 268 k | ﹤0.01% | 1599 |
|
|
2022
Q2 | USD 2.13 M | Compra |
151,015
+17,571
| +13% | +USD 328 k | ﹤0.01% | 1734 |
|
|
2022
Q1 | USD 3.23 M | Compra |
133,444
+5,011
| +4% | +USD 121 k | ﹤0.01% | 1571 |
|
|
2021
Q4 | USD 3 M | Venta |
128,433
-1,740
| -1% | -USD 35 k | ﹤0.01% | 1663 |
|
|
2021
Q3 | USD 2.16 M | Compra |
130,173
+1,651
| +1% | +USD 31.8 k | ﹤0.01% | 1872 |
|
|
2021
Q2 | USD 3.14 M | Compra |
128,522
+12,840
| +11% | +USD 290 k | ﹤0.01% | 1700 |
|
|
2021
Q1 | USD 2.98 M | Venta |
115,682
-9,114
| -7% | -USD 401 k | ﹤0.01% | 1710 |
|
|
2020
Q4 | USD 6.67 M | Compra |
124,796
+100
| +0.1% | +USD 4.96 k | 0.01% | 1186 |
|
|
2020
Q3 | USD 5.14 M | Venta |
124,696
-7,515
| -6% | -USD 325 k | 0.01% | 1152 |
|
|
2020
Q2 | USD 6.41 M | Venta |
132,211
-30,324
| -19% | -USD 1.46 M | 0.01% | 1051 |
|
|
2020
Q1 | USD 6.87 M | Compra |
162,535
+1,758
| +1% | +USD 72.4 k | 0.01% | 846 |
|
|
2019
Q4 | USD 6.88 M | Compra |
160,777
+13,709
| +9% | +USD 596 k | 0.01% | 1068 |
|
|
2019
Q3 | USD 5.29 M | Venta |
147,068
-3,462
| -2% | -USD 105 k | 0.01% | 1158 |
|
|
2019
Q2 | USD 4.02 M | Compra |
150,530
+462
| +0.3% | +USD 11.8 k | 0.01% | 1321 |
|
|
2019
Q1 | USD 4.03 M | Compra |
150,068
+17,252
| +13% | +USD 403 k | 0.01% | 1300 |
|
|
2018
Q4 | USD 2.15 M | Compra |
132,816
+44,513
| +50% | +USD 864 k | ﹤0.01% | 1600 |
|
|
2018
Q3 | USD 1.83 M | Venta |
88,303
-6,015
| -6% | -USD 94.6 k | ﹤0.01% | 1707 |
|
|
2018
Q2 | USD 1.44 M | Venta |
94,318
-7,910
| -8% | -USD 141 k | ﹤0.01% | 1851 |
|
|
2018
Q1 | USD 2.3 M | Venta |
102,228
-6,132
| -6% | -USD 170 k | ﹤0.01% | 1519 |
|
|
2017
Q4 | USD 3.26 M | Venta |
108,360
-2,734
| -2% | -USD 87.4 k | 0.01% | 1329 |
|
|
2017
Q3 | USD 4.18 M | Venta |
111,094
-4,682
| -4% | -USD 152 k | 0.01% | 1146 |
|
|
2017
Q2 | USD 3.23 M | Venta |
115,776
-1,573
| -1% | -USD 46.9 k | 0.01% | 1271 |
|
|
2017
Q1 | USD 4.03 M | Venta |
117,349
-340
| -0.3% | -USD 12 k | 0.01% | 1140 |
|
|
2016
Q4 | USD 3.39 M | Compra |
117,689
+9,006
| +8% | +USD 238 k | 0.01% | 1141 |
|
|
2016
Q3 | USD 3.46 M | Compra |
108,683
+9,653
| +10% | +USD 327 k | 0.01% | 1091 |
|
|
2016
Q2 | USD 3.22 M | Compra |
99,030
+18,190
| +23% | +USD 609 k | 0.01% | 1060 |
|
|
2016
Q1 | USD 2.26 M | Compra |
80,840
+6,150
| +8% | +USD 134 k | 0.01% | 1290 |
|
|
2015
Q4 | USD 2.66 M | Compra |
74,690
+1,715
| +2% | +USD 60.4 k | 0.01% | 1170 |
|
|
2015
Q3 | USD 2.41 M | Compra |
72,975
+1,522
| +2% | +USD 63.3 k | 0.01% | 1214 |
|
|
2015
Q2 | USD 2.99 M | Venta |
71,453
-2,800
| -4% | -USD 108 k | 0.01% | 1145 |
|
|
2015
Q1 | USD 2.42 M | Compra |
74,253
+11,685
| +19% | +USD 402 k | 0.01% | 1272 |
|
|
2014
Q4 | USD 1.99 M | Venta |
62,568
-595
| -0.9% | -USD 16.9 k | 0.01% | 1350 |
|
|
2014
Q3 | USD 1.56 M | Venta |
63,163
-4,090
| -6% | -USD 95.7 k | ﹤0.01% | 1490 |
|
|
2014
Q2 | USD 1.52 M | Compra |
67,253
+4,996
| +8% | +USD 104 k | ﹤0.01% | 1555 |
|
|
2014
Q1 | USD 1.52 M | Venta |
62,257
-3,240
| -5% | -USD 82 k | ﹤0.01% | 1533 |
|
|
2013
Q4 | USD 1.64 M | Compra |
65,497
+3,270
| +5% | +USD 77.1 k | ﹤0.01% | 1492 |
|
|
2013
Q3 | USD 1.71 M | Compra |
62,227
+8,827
| +17% | +USD 185 k | 0.01% | 1446 |
|
|
2013
Q2 | USD 969 k | Compra |
+53,400
| Nuevas | +USD 736 k | ﹤0.01% | 1786 |
|
Otros fondos que tienen ACAD en su portafolio
BBA
Posición de RhumbLine Advisers en ACAD: resumen de T3 2026
RhumbLine Advisers aumentó su participación en Acadia Pharmaceuticals (ACAD) en 9.1% durante T3 2026, al comprar aproximadamente USD 742 k y elevar la posición a 330,546 acciones con un valor de USD 6.66 M. La posición representa 0.01% del portafolio y ocupa el puesto #1274.
RhumbLine Advisers reportó por primera vez una posición en ACAD en T2 2013 y desde entonces la ha mantenido en 54 trimestres. La posición alcanzó su máximo de USD 9.6 M en T4 2025. Al cierre de T3 2026, 351 fondos que sigue Wall St. Rank mantienen una posición en ACAD.
- Al cierre de T3 2026, RhumbLine Advisers tenía 330,546 acciones de Acadia Pharmaceuticals con un valor de USD 6.66 M.
- RhumbLine Advisers compró 27,644 acciones de Acadia Pharmaceuticals en T3 2026, por un monto estimado de USD 742 k.
- Acadia Pharmaceuticals representó el 0.01% del portafolio de RhumbLine Advisers en T3 2026 y fue su posición número 1274.
- RhumbLine Advisers reportó por primera vez una posición en Acadia Pharmaceuticals en T2 2013 y desde entonces la ha mantenido en 54 trimestres.
- La posición de RhumbLine Advisers en Acadia Pharmaceuticals alcanzó su máximo de USD 9.6 M en T4 2025.
- Al cierre de T3 2026, 351 fondos que sigue Wall St. Rank tenían Acadia Pharmaceuticals en su portafolio.
Según el informe 13F de RhumbLine Advisers correspondiente a T3 2026, presentado el 10 nov 2026.